Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.97K
+0.70%-2.68%+20.76%+10.59% 216B
-0.75%-3.10%-3.83%-20.05% 142B
+1.66%-1.11%-17.56%+38.75% 138B
-0.16%+0.21%-50.22%+2.20% 74.53B
+0.84%-2.26%+16.91%+19.54% 52.34B
+1.18%-0.33%-16.45%-13.29% 50.28B
+0.32%-0.41%+26.01%+24.84% 41.93B
-0.72%-2.45%+39.89%+49.94% 40.06B
+1.10%+0.32%-0.26%+6.76% 32.69B
Average +0.39%-0.52%+1.69%+13.25% 87.63B
Weighted average by Cap. +0.47%-1.16%+0.66%+10.86%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
7
  1. Stock Market
  2. Stocks
  3. SCIE Stock